Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
|08 Oct 2021||$0.1200||100.00%||Final||29 Oct 2021|
|24 Mar 2021||$0.1200||100.00%||Interim||15 Apr 2021|
|25 Mar 2020||$0.1200||100.00%||Interim||30 Nov 2020|
|03 Oct 2019||$0.1200||100.00%||Final||25 Oct 2019|
|28 Mar 2019||$0.1200||100.00%||Interim||18 Apr 2019|
|13 Sep 2018||$0.1200||100.00%||Final||12 Oct 2018|
|28 Mar 2018||$0.1400||100.00%||Interim||17 Apr 2018|
|14 Sep 2017||$0.1200||100.00%||Final||13 Oct 2017|
|30 Mar 2017||$0.1300||100.00%||Interim||18 Apr 2017|
|15 Sep 2016||$0.1500||100.00%||Final||14 Oct 2016|
|31 Mar 2016||$0.1400||100.00%||Interim||15 Apr 2016|
|30 Sep 2015||$0.1400||100.00%||16 Oct 2015|
|31 Mar 2015||$0.1300||100.00%||15 Apr 2015|
|30 Sep 2014||$0.1400||100.00%||Final||16 Oct 2014|
|31 Mar 2014||$0.1200||100.00%||Interim||17 Apr 2014|
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Virtus Health Ltd is an Australian company engaged in the provision of healthcare services like fertility services, medical day procedure services, and medical diagnostic services. Its operating segment includes Healthcare Services Australia and Healthcare Services International. The company generates maximum revenue from the Healthcare Services Australia segment.
|12 Oct 2021||$5.45||$-0.05||-0.91%||323,810||$5.66||$5.66||$5.37|
|11 Oct 2021||$5.50||$-0.16||-2.83%||176,578||$5.63||$5.65||$5.46|
|08 Oct 2021||$5.66||$-0.11||-1.91%||342,121||$5.66||$5.72||$5.52|
|07 Oct 2021||$5.77||$0.13||2.30%||247,962||$5.70||$5.82||$5.66|
|06 Oct 2021||$5.64||$-0.01||-0.18%||268,064||$5.70||$5.87||$5.62|
|05 Oct 2021||$5.65||$-0.11||-1.91%||316,967||$5.68||$5.75||$5.60|
|04 Oct 2021||$5.76||$-0.04||-0.69%||132,012||$5.91||$5.91||$5.71|
|01 Oct 2021||$5.80||$-0.11||-1.86%||262,164||$5.85||$5.90||$5.76|
|30 Sep 2021||$5.91||$0.10||1.72%||306,559||$5.85||$5.91||$5.79|
|29 Sep 2021||$5.81||$-0.06||-1.02%||381,357||$5.87||$5.93||$5.77|
|28 Sep 2021||$5.87||$-0.01||-0.17%||312,610||$5.92||$5.98||$5.84|
|27 Sep 2021||$5.88||$0.18||3.16%||316,096||$5.70||$5.93||$5.69|
|24 Sep 2021||$5.70||$-0.17||-2.90%||463,114||$5.86||$5.87||$5.61|
|23 Sep 2021||$5.87||$0.09||1.56%||287,798||$5.78||$5.97||$5.78|
|22 Sep 2021||$5.78||$-0.02||-0.34%||396,479||$5.70||$5.84||$5.70|
|21 Sep 2021||$5.80||$-0.08||-1.36%||400,164||$5.86||$5.88||$5.64|
|20 Sep 2021||$5.88||$-0.04||-0.68%||262,663||$5.92||$6.06||$5.84|
|17 Sep 2021||$5.92||$-0.07||-1.17%||460,298||$5.92||$5.98||$5.82|
|16 Sep 2021||$5.99||$0.04||0.67%||165,074||$5.95||$6.02||$5.92|
|15 Sep 2021||$5.95||$0.00||0.00%||332,071||$5.92||$5.99||$5.89|
|14 Sep 2021||$5.95||$-0.06||-1.00%||140,798||$6.01||$6.01||$5.90|
|25 Mar 2021||Kate Munnings||Issued||54||$310,574|| |
Conversion of securities.
|25 Mar 2021||Kate Munnings||Exercise||54||$310,574|| |
Conversion of securities. 312,106 - Performance Rights
|19 Mar 2021||Greg Couttas||Buy||5||$29,650|| |
|23 Nov 2020||Kate Munnings||Issued||204||$1,110,206|| |
Issue of securities. 366,119 - Performance Rights
|Ms Kate Munnings||Chief Executive OfficerExecutive Director||Mar 2020|| |
Ms Munnings has a breadth of experience spanning more than 30 years. Recently, she led strategy, hospital operations and a organisational change program as Chief Operating Officer of Ramsay Health Care Australia. As Chief Executive, Operations at Transfield Services, she led a portfolio of government contracts across Australia, New Zealand and Melanesia. She was a partner at law firms, Corrs Chambers Westgarth and Baker McKenzie; specialising in construction law and also had spend eight years as Chief Risk and Legal Officer/Company Secretary at Transfield Services, focussed on corporate law, risk management and management. Previously in her career she specialized in HIV/AIDS. She is a Director of Digital Health Co-operative Research Centre.
|Mr Lyndon Grant Hale||Executive Director||May 2013|| |
Mr Hale has been the Medical Director of Melbourne IVF Pty Ltd since 2008. He is also director of Reproductive Surgery at The Women's Hospital. He has knowledge & approach and brings experience in assisted reproduction treatments to the care of his patients. He is a member of the Risk Committee.
|Ms Sonia Petering||Non-Executive DirectorNon-Executive Chairman||Sep 2014|| |
Ms Petering has more than 15 years experience in non executive director and chair roles with listed and unlisted companies and government authorities across finance services, payments, insurance, professional services and healthcare. She commenced her legal practice in 2001. She previously served as a non executive director on the boards of Transport Accident Commission of Victoria and Rural Finance Corporation of Victoria and as Chair of the Board of Rural Finance Corporation from 2009 - 2016. Sonia is also a non executive director of TAL Dai-ichi Australia Ltd and Cuscal Ltd. She is a member of the Risk Committee.
|Mr Greg Couttas||Non-Executive Director||Oct 2016|| |
Mr Couttas has had spend 40 years with Deloitte including 28 years as partner. In his years at Deloitte he worked in audit across sectors, specialising in ASX100 clients. His expertise includes accounting, finance, auditing, risk management, corporate governance, capital markets and due diligence. Additionally, he held a number of management roles at Deloitte including being the Managing Partner for NSW from 2005 to 2008, chairing the Audit and Risk Committee for eleven years, and was a Member of the Board of Partners for Deloitte Australia from 2005 to 2016. He is also a director of Sydney Water Corporation, Hireup Pty Limited and a member of the Governance Board of The Salvation Army Australia Territory. He is a member of the Risk Committee.
|Mr Shane Solomon||Non-Executive Director||Sep 2018|| |
Mr Solomon is a healthcare professional having worked in Executive and Board roles across the public and private health sector over the last 34 years. He brings health policy and a understanding of clinic governance gained from his roles in the Victorian public health system including the role of Undersecretary for Health, and Chief Executive of the Hong Kong Hospital Authority. Returning to Australia in 2010, he became a Partner at KPMG Australia, and has had led the National Health practice and in 2013, he became founder and Managing Director of Telstra's eHealth business, Telstra Health. He was serving in 2011 as a Chairman of the Independent Hospital Pricing Authority he maintains this role and is on the Board of Silver Chain. He also chairs the SA Health EMR Project Board. He Chair of the Risk Committee.
|Ms Catherine (Cathy) Ann Aston||Non-Executive Director||Sep 2021|| |
Ms Aston had an executive career at Telstra where she moved across roles in finance, marketing and strategy, including as the Finance Director of the International Division where she was based in Hong Kong and New Delhi and as Chief Executive of a mobile phone company based in Colombo. Cathy's executive roles each had a focus on enabling the business to improve its customer service and to operate more effectively and efficiently through better use of technology. Since 2013, Cathy has held a range of non-executive director roles and has also worked as a business advisor with a range of clients. Most recently, Cathy has worked with the NSW Government to improve outcomes across an array of programs and is currently a nonexecutive director with Macquarie Investment Management Ltd, IMB Bank Ltd, IVE Group (ASX: IGL) and Over the Wire Holdings (ASX: OTW), with the latter two roles also including Chair of Audit, Risk and Compliance committees. Cathy's non-executive director experience also includes serving as an Advisory Board Member of Avanseus, an AI business based out of Singapore.
|Dr Priscilla Rogers||Non-Executive Director||Sep 2021|| |
Dr Rogers has had direct experience in how technology innovation can transform industries and improve lives. She has spent her career in the research, development and translation of new technologies including medical devices, artificial intelligence (AI) and digital health solutions, including leading the Cognitive Health & Life Sciences portfolio at IBM Research Australia. Priscilla is currently a director and co-founder of Doftek, which is commercializing the active wheel alignment systems for vehicles; as well as a director and co-founder of Grean Brands, which is a health and wellness company responsible for developing and commercializing new antimicrobial prevention products. Priscilla previously co-founded IntelliMedical, which developed steerable guide wires for minimally invasive surgical procedures and was acquired by Merit Medical (NASDAQ: MMSI) in 2017. Priscilla's non-executive director roles include serving on the Board of the Digital Health Cooperative Research Centre and the Board of Australian Dementia Network Limited.
|Ms Ava Bentley||Group General Manager-Legal & RiskCompany Secretary||May 2021|| |
|Richard Banks||Chief Strategy Officer and European Managing Director|| |
|Ava Bentley||Group General Manager-Legal & RiskCompany Secretary|| |
|Allan Gray Investment Mgt||9,097,150||11.30%|
|Dimensional Fund Advisors||4,196,212||5.20%|
|Vinva Investment Mgt||3,727,912||4.60%|
|Merlon Capital Partners||3,035,750||3.80%|
|Renaissance Smaller Companies||2,418,323||3.00%|
|Tribeca Investment Partners||2,126,483||2.60%|
|Norges Bank Investment Mgt||1,719,024||2.10%|
|Vanguard Investments Australia||1,436,492||1.80%|
|Wilson Asset Mgt||1,303,691||1.60%|
|Acadian Asset Mgt (Australia)||995,532||1.20%|
|Mr Lyndon G Hale||826,572||1.00%|
|Citigroup Global Markets||820,476||1.00%|
|Auscap Asset Mgt||767,720||1.00%|
|JPMorgan Securities Australia||702,079||0.90%|
|Mr Francis Quinn||689,375||0.90%|
|LSV Asset Mgt||686,255||0.90%|
|Segall Bryant Hamill Investment Coun||655,825||0.80%|